Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Exelixis, Inc.'s quarterly P/E stands at 14.3x, down 11.8% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 14.0% YoY to 11.2x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 15.85 | 14.32 | 17.75 | 15.71 | 17.71 | 16.22 | 7.30 | 49.44 | 22.21 | 1655.30 | 19.11 | 40.44 | — |
| — | -11.8% | +143.3% | -68.2% | -20.3% | -99.0% | -61.8% | +22.3% | — | +9612.2% | -22.0% | +48.4% | — | |
| P/S Ratio | 5.09 | 4.67 | 5.77 | 4.48 | 4.31 | 3.51 | 2.59 | 4.26 | 3.91 | 3.70 | 3.33 | 3.87 | 3.06 |
| — | +33.2% | +122.8% | +5.2% | +10.2% | -5.1% | -22.1% | +10.1% | +28.0% | +19.4% | -20.3% | -25.5% | -6.6% | |
| P/B Ratio | 5.75 | 5.17 | 6.45 | 4.67 | 4.36 | 3.33 | 3.12 | 3.41 | 3.32 | 2.97 | 2.47 | 2.48 | 2.08 |
| — | +55.4% | +107.1% | +37.2% | +31.3% | +11.9% | +25.9% | +37.5% | +59.2% | +45.2% | -15.6% | -23.2% | -22.0% | |
| P/FCF | 13.36 | 9.66 | 66.97 | 13.18 | 10.80 | 7.22 | 17.43 | 35.80 | — | 74.23 | 13.77 | 44.12 | — |
| — | +33.9% | +284.2% | -63.2% | — | -90.3% | +26.6% | -18.9% | — | +494.3% | -85.2% | +238.9% | — | |
| EV / EBITDA | 13.19 | 11.24 | 14.87 | 12.83 | 14.26 | 13.07 | 5.83 | 50.17 | 21.05 | — | 17.84 | 41.89 | — |
| — | -14.0% | +155.0% | -74.4% | -32.2% | — | -67.3% | +19.8% | — | — | -3.5% | +118.5% | — | |
| EV / EBIT | 13.19 | 10.86 | 14.26 | 13.33 | 14.91 | 9.99 | 5.98 | 28.86 | 22.73 | — | 19.22 | 51.85 | — |
| — | +8.8% | +138.6% | -53.8% | -34.4% | — | -68.9% | -44.3% | — | — | -1.6% | +156.6% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Exelixis, Inc.'s operating margin was 39.6% in Q3 2025, up 2.0 pp QoQ and up 14.4 pp YoY. This marks the 5th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 34.9% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 96.9% | 96.6% | 96.5% | 96.5% | 96.8% | 97.2% | 95.0% | 95.5% | 96.0% | 96.2% | 96.5% | 96.2% |
| — | +0.1% | -0.7% | +1.6% | +1.1% | +0.8% | +1.0% | -1.6% | -0.8% | -0.3% | -0.6% | +0.2% | -0.9% | |
| Operating Margin | 37.6% | 39.6% | 37.6% | 33.6% | 28.8% | 25.2% | 43.3% | 6.9% | 17.1% | -3.7% | 16.6% | 7.1% | -11.3% |
| — | +56.9% | -13.2% | +385.5% | +68.9% | +776.9% | +161.3% | -1.8% | +250.3% | -118.6% | -17.0% | -69.8% | -143.9% | |
| Net Margin | 33.7% | 32.4% | 32.5% | 28.7% | 24.7% | 21.9% | 35.5% | 8.8% | 17.8% | 0.2% | 17.3% | 9.8% | -7.1% |
| — | +48.1% | -8.3% | +227.5% | +38.4% | +9811.8% | +105.4% | -10.4% | +350.5% | -98.8% | +2.5% | -49.2% | -133.7% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 35.5% | 9.2% | 8.9% | 7.3% | 6.2% | 5.4% | 10.6% | 1.7% | 3.7% | 0.0% | 3.2% | 1.6% | -1.2% |
| — | +71.9% | -16.6% | +329.4% | +66.9% | +12472.1% | +233.3% | +7.1% | +406.1% | -98.6% | +5.9% | -47.9% | -127.5% | |
| ROA | 27.0% | 7.0% | 6.7% | 5.5% | 4.7% | 4.1% | 8.1% | 1.3% | 2.9% | 0.0% | 2.6% | 1.3% | -1.0% |
| — | +71.0% | -17.3% | +324.8% | +63.9% | +12003.8% | +214.0% | +0.8% | +388.9% | -98.6% | +1.2% | -50.5% | -126.6% | |
| ROIC | 32.1% | 8.8% | 7.7% | 6.4% | 5.5% | 4.7% | 9.9% | 1.0% | 2.8% | -0.6% | 2.6% | 1.0% | -1.7% |
| — | +87.7% | -22.5% | +520.9% | +95.2% | +886.2% | +277.2% | +5.0% | +263.1% | -118.9% | -26.0% | -74.4% | -131.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Exelixis, Inc.'s Debt/EBITDA ratio is 0.7x, down from 0.8x last quarter — comfortably within a safe range.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | 0.08 | 0.08 | 0.07 | 0.08 |
| — | -4.4% | -5.3% | -7.3% | +1.3% | +5.1% | +21.3% | +29.4% | +9.8% | +26.7% | +14.4% | +231.4% | +229.5% | |
| Debt / EBITDA | 0.20 | 0.72 | 0.81 | 0.96 | 1.12 | 1.35 | 0.70 | 5.62 | 2.15 | — | 2.32 | 5.24 | — |
| — | -46.6% | +16.4% | -82.9% | -48.1% | — | -69.9% | +7.3% | — | — | +27.5% | +807.7% | — | |
| Current Ratio | 3.56 | 3.75 | 3.51 | 3.50 | 3.63 | 3.93 | 4.27 | 3.46 | 3.34 | 3.83 | 4.68 | 5.00 | 4.99 |
| — | -4.5% | -17.8% | +1.0% | +8.7% | +2.6% | -8.7% | -30.7% | -33.0% | -37.2% | -23.0% | -21.6% | -8.2% | |
| Quick Ratio | 3.50 | 3.68 | 3.44 | 3.44 | 3.58 | 3.88 | 4.21 | 3.41 | 3.30 | 3.76 | 4.60 | 4.91 | 4.89 |
| — | -5.1% | -18.3% | +0.8% | +8.5% | +3.0% | -8.4% | -30.6% | -32.5% | -37.4% | -23.0% | -21.8% | -8.7% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonExelixis, Inc.'s current P/E is 15.8x. The average P/E over the last 4 quarters is 16.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Exelixis, Inc.'s current operating margin is 37.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Exelixis, Inc.'s business trajectory between earnings reports.